BioXcel Therapeutics (NASDAQ:BTAI) received a $25.00 target price from analysts at HC Wainwright in a research note issued on Tuesday, February 5th. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 184.41% from the stock’s current price.
Separately, Zacks Investment Research cut shares of BioXcel Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $18.67.
BTAI traded up $0.31 during midday trading on Tuesday, reaching $8.79. The company’s stock had a trading volume of 86,300 shares, compared to its average volume of 89,756. BioXcel Therapeutics has a 1 year low of $2.41 and a 1 year high of $14.79.
In other BioXcel Therapeutics news, Director Peter Mueller purchased 8,795 shares of the firm’s stock in a transaction on Friday, December 7th. The shares were acquired at an average cost of $5.01 per share, for a total transaction of $44,062.95. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired 17,202 shares of company stock worth $85,838 over the last quarter.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Artemis Investment Management LLP grew its position in BioXcel Therapeutics by 1.3% during the 3rd quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock worth $9,700,000 after purchasing an additional 16,358 shares during the last quarter. BlackRock Inc. acquired a new stake in BioXcel Therapeutics in the second quarter valued at approximately $137,000. Finally, Creative Planning acquired a new stake in BioXcel Therapeutics in the third quarter valued at approximately $102,000. Institutional investors and hedge funds own 20.12% of the company’s stock.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Recommended Story: Why is the ex-dividend date different from the record date?
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.